General Information of Drug (ID: DMP8TKA)

Drug Name
CY-208243 Drug Info
Synonyms
Indolophenanthridine; CY 208-243; 100999-26-6; CY-208-243; 4,6,6a,7,8,12b-Hexahydro-7-methylindolo(4,3-ab)-phenanthridine; Indolo(4,3-ab)phenanthridine, 4,6,6a,7,8,12b-hexahydro-7-methyl-, trans-(-)-; (6aR,12bR)-7-methyl-4,6,6a,7,8,12b-hexahydroindolo[4,3-ab]phenanthridine; Tocris-1249; AC1L1ODE; Biomol-NT_000032; AC1Q1IN1; CHEMBL313737; BPBio1_001225; SCHEMBL9364562; DTXSID9042598; CHEBI:93399; MolPort-003-983-825; HMS3267H13; ZINC26501186; AKOS024456489; API0009347; NCGC00025078-01; NCGC00025078-02; LS-183405
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
58144
ChEBI ID
CHEBI:93399
CAS Number
CAS 100999-26-6
TTD Drug ID
DMP8TKA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Dopamine D1 receptor (D1R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [4]
Pergolide DM14MAE Parkinson disease 8A00.0 Approved [5]
Methylergonovine DMBEX4O Spontaneous abortion JA00.0 Approved [6]
Fenoldopam DMFAOKP Hypertension BA00-BA04 Approved [7]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [8]
Ecopipam DMS9R43 Cocaine addiction 6C45.2 Phase 3 [9]
DAS-431 DMM3BPL Dementia 6D80-6D86 Phase 2 [10]
Dihydrexidine DMACPQO Psychotic disorder 6A20-6A25 Phase 1/2 [11]
BAM-1110 DMPMKUF Parkinson disease 8A00.0 Discontinued in Phase 2 [12]
ZELANDOPAM HYDROCHLORIDE DM1QXPE Hypertension BA00-BA04 Discontinued in Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apomorphine SL DMPH7EO Discovery agent N.A. Investigative [14]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D1 receptor (D1R) TTZFYLI DRD1_HUMAN Agonist [2] , [3]
Neuron-specific vesicular protein calcyon (CALY) TT0R12H CALY_HUMAN Activator [3]

References

1 Decrease of behavioral and biochemical denervation supersensitivity of rat striatum by nigral transplants. Neuroscience. 1991;44(1):75-83.
2 The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206.
3 Dopamine D1 receptor agonists induce penile erections in rats. Eur J Pharmacol. 2003 Jan 26;460(1):71-4.
4 Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
7 Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
8 Clinical pipeline report, company report or official report of Lundbeck.
9 A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
10 Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
11 trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
12 Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
13 Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. Eur J Pharmacol. 2005 Mar 7;510(1-2):121-6.
14 Dopamine and sexual function. Int J Impot Res. 2001 Aug;13 Suppl 3:S18-28.